Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
ASCO Immunotherapy Roundup - 8: 5 Immune Checkpoint Inhibitors Projected to Rake in 2 Trillion Yen in 2020
Global sales of five immune checkpoint inhibitors are forecast to reach 2 trillion yen in 2020, according to EvaluatePharma, a London-based market research firm specializing in the pharmaceutical industry. In the eighth of this series, Hiroshi Yamazaki, business development director…
To read the full story
Related Article
- ASCO Immunotherapy Roundup - 9: Researcher Says Predominance of Anti-PD-1 Antibodies Not Assured
September 1, 2015
- ASCO Immunotherapy Roundup - 7: Patient Group Hails Dawn of New Cancer Treatment Era
August 14, 2015
- ASCO Immunotherapy Roundup - 6: CAR T-Cell Therapy Another Hot Field in Immuno-Oncology
August 12, 2015
- ASCO Immunotherapy Roundup - 5: Merck & Co. Discovers New Biomarkers for Keytruda
August 7, 2015
- ASCO Immunotherapy Roundup - 4: Merck KGaA Trailing Rivals with ADCC-Inducing Avelumab
July 30, 2015
- ASCO Immunotherapy Roundup - 3: AZ Set to Harness Rich Pipeline to Pursue Combo Strategy
July 16, 2015
- ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
- ASCO Immunotherapy Roundup - 1: Opdivo Data Boost Confidence in BMS’s Combination Strategy
July 7, 2015
BUSINESS
- BeiGene Sees Better-than-Expected Uptake for Brukinsa after March Launch
April 23, 2025
- CSL to Join Forces with Specialists to Raise Awareness of HAE: Japan President
April 23, 2025
- Takeda’s Japan Earnings Bottomed Out, Now on Pace to Growth from FY2025: Head
April 23, 2025
- Fujifilm CDMO Strikes US$3 Billion Manufacturing Deal with Regeneron
April 23, 2025
- Vital-Net Bags Japan Rights to Shield’s Iron Deficiency Med
April 23, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…